Paclitaxel Protein-bound Particles Injection, Powder, Lyophilized, For Suspension
Product Images NDC 69097-398

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Paclitaxel Protein-bound Particles (NDC 69097-398). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (246854f7 9f4b 45f2 Aa64 D482a256bf56 01)

Chemical structure diagram depicting the molecular structure of paclitaxel protein-bound particles, showing its characteristic complex ring system and functional groups.*

FDA Label Image

100ml Label (246854f7 9f4b 45f2 Aa64 D482a256bf56 02)

Label for Paclitaxel protein-bound particles injection, powder, lyophilized, for suspension, albumin-bound, 100 mg per vial. It is for intravenous use only and labeled for single-dose vial use. The label includes instructions to discard unused portion and notes that functional properties differ from other paclitaxel products. Manufactured by Cipla USA Inc., the label also lists storage instructions, dosage form details, and a barcode.*

FDA Label Image

100ml-carton (246854f7 9f4b 45f2 Aa64 D482a256bf56 03)

Paclitaxel protein-bound particles 100 mg per vial injection powder lyophilized for suspension (albumin-bound) in a single-dose vial carton. Label indicates intravenous use only, with directions to discard any unused portion. The product is labeled with Cipla as the manufacturer, includes warnings not to substitute for other paclitaxel products, and cautions on storage and usage instructions.*

FDA Label Image

Image (246854f7 9f4b 45f2 Aa64 D482a256bf56 164 2)

An instructional illustration showing a syringe drawing liquid from a vial, likely representing the preparation of an intravenous injection suspension. The vial is tilted slightly, and the syringe needle is inserted through the vial's rubber stopper.*

FDA Label Image

Image (246854f7 9f4b 45f2 Aa64 D482a256bf56 233 1)

A survival curve chart depicting the proportion of survival over time in months for two treatment groups: Paclitaxel/gemcitabine and Gemcitabine. The x-axis shows time in months, and the y-axis shows the proportion of survival from 0 to 1. The graph visually compares survival rates between the two groups across the time period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.